Pneumonia Treatment for a 13-Year-Old in the PICU
For a 13-year-old in the PICU with pneumonia, start empiric IV therapy with ampicillin (150-200 mg/kg/day divided every 6 hours) or ceftriaxone (50-100 mg/kg/day divided every 12-24 hours) PLUS azithromycin (10 mg/kg on days 1-2, then transition to oral if possible) to cover both typical bacterial pathogens and atypical organisms like Mycoplasma and Chlamydophila. 1
Empiric Antibiotic Selection Algorithm
The PICU setting demands broad initial coverage given the severity of illness. Your approach should follow this decision tree:
First-Line Combination Therapy
- β-lactam backbone: Ampicillin (150-200 mg/kg/day every 6 hours) OR ceftriaxone (50-100 mg/kg/day every 12-24 hours) 1
- PLUS macrolide: IV azithromycin (10 mg/kg on days 1 and 2) for atypical coverage, as M. pneumoniae and C. pneumoniae are significant considerations in this age group 1
Add MRSA Coverage If:
- Local MRSA prevalence is high
- Necrotizing pneumonia or empyema is present
- Recent influenza infection
- Severe sepsis/septic shock
Add vancomycin (40-60 mg/kg/day every 6-8 hours, targeting AUC/MIC >400) OR clindamycin (40 mg/kg/day every 6-8 hours) based on local susceptibility patterns 1
Pathogen-Specific Adjustments
Once cultures return, narrow therapy based on identified organisms:
Streptococcus pneumoniae (Most Common)
- Penicillin-susceptible (MIC ≤2.0): Continue ampicillin or switch to penicillin (200,000-250,000 U/kg/day every 4-6 hours) 1
- Penicillin-resistant (MIC ≥4.0): Ceftriaxone 100 mg/kg/day is preferred; third-generation cephalosporins remain effective despite resistance 1
Staphylococcus aureus
- MSSA: Cefazolin (150 mg/kg/day every 8 hours) or oxacillin (150-200 mg/kg/day every 6-8 hours) 1
- MRSA: Vancomycin (dose to AUC/MIC >400) or clindamycin if susceptible 1
Atypical Organisms
- Continue azithromycin for confirmed Mycoplasma or Chlamydophila 1
- For children >7 years, doxycycline (2-4 mg/kg/day in 2 doses) is an alternative 1
Duration of Therapy
Treat for 6-7 days in most cases. Recent pediatric PICU data shows that a 6-7 day course (median 6 days) achieves excellent outcomes with only 1% day-7 mortality and 10% recurrence rate 2. This aligns with adult VAP guidelines recommending short-course therapy 3.
- Uncomplicated pneumonia: 6-7 days total
- Complicated pneumonia with empyema: May require longer duration, but reassess at day 7
- Clinical stability criteria: Afebrile for 24 hours, improving respiratory status, tolerating oral intake
Critical Pitfalls to Avoid
Don't skip macrolide coverage initially: At age 13, atypical organisms are common and empiric combination therapy improves outcomes 1
Don't use vancomycin as first-line for pneumococcus: Third-generation cephalosporins remain highly effective even for resistant strains in North America 1
Don't over-treat with prolonged antibiotics: Studies show 6-7 days is sufficient for most PICU pneumonia cases without adverse outcomes 2. Longer courses increase resistance without improving mortality.
Don't delay MRSA coverage if indicated: If necrotizing features, empyema, or post-influenza pneumonia are present, add vancomycin or clindamycin immediately 1
Transition to Oral Therapy
Once clinically stable (afebrile >24 hours, improved work of breathing, tolerating PO):
- For pneumococcus: Amoxicillin 90 mg/kg/day in 2 doses 1
- For atypicals: Continue oral azithromycin (5 mg/kg/day once daily days 2-5) 1
- For MRSA: Clindamycin 30-40 mg/kg/day in 3-4 doses OR linezolid 20 mg/kg/day in 2 doses (for age ≥12 years) 1
Evidence Quality Note
These recommendations come from the 2011 PIDS/IDSA guidelines [1-1, which remain the definitive pediatric pneumonia guidelines. While dated, they represent the highest-quality guideline evidence available. Adherence to these guidelines significantly reduces PICU length of stay (9.3 vs 13.7 days) and ventilation duration without increasing mortality 4.